Erbitux Fails First-Line Pancreatic Cancer Trial, But ImClone/Bristol Will Move Program Forward
This article was originally published in The Pink Sheet Daily
Executive Summary
Cetuximab is currently being evaluated in nine other Phase I and II trials for pancreatic cancer, which will continue.
You may also be interested in...
Erbitux Misses Primary Endpoint As First-Line Treatment In Phase III NSCLC Trial
Bristol-Myers Squibb/ImClone’s future for Erbitux in first-line NSCLC hinges on FLEX study findings, scheduled for release in first half of 2008.
Erbitux Misses Primary Endpoint As First-Line Treatment In Phase III NSCLC Trial
Bristol-Myers Squibb/ImClone’s future for Erbitux in first-line NSCLC hinges on FLEX study findings, scheduled for release in first half of 2008.
Erbitux Shows Survival Benefit With Chemo In First-Line Metastatic Head & Neck Cancer
ImClone/Bristol will discuss potential for submitting an sBLA for the indication with FDA.